玻璃体腔内注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿

Clinical observation of intravitreal injection of Conbercept for the treatment of macular edema secondary to retinal vein occlusion

目的:观察玻璃体腔内注射康柏西普治疗视网膜静脉阻塞(retinal vein occlusion,RVO)继发黄斑水肿的临床效果及安全性。方法:回顾性观察我院2016-01/03间收治的RVO继发黄斑水肿的患者22例22眼,3mo内给予3次玻璃体腔内注射康柏西普0.05m L(0.5mg),比较治疗前后患者的视力变化情况,光学相干断层扫描(OCT)检查,眼底荧光造影(FFA)及眼底出血吸收情况。结果:所选患者玻璃体内注射康柏西普在1wk,1、2、3mo后平均视力均有不同程度的提高,差异有统计学意义(P<0.05)。OCT图像显示黄斑中心凹视网膜厚度明显变薄,与治疗前相比差异具有统计学意义(P<0.05)。治疗后3mo检查FFA显示视网膜渗漏明显减轻,眼底出血明显吸收。结论:玻璃体腔内注射抗VEGF药物康柏西普治疗RVO继发的黄斑水肿疗效肯定,但远期疗效及注射药物的频率尚需进一步观察与探讨。

AIM：To investigate the clinical effect and safety of intravitreal injection of Conbercept for the treatment of macular edema secondary to retinal vein obstruction.METHODS： A total of 22 patients with macular edema secondary to retinal vein occlusion were treated in our hospital during January 2016 to M arth 2016. A total of 22 patients were given three intravitreal injections of Conbercept 0. 05 mL（ 0. 5mg）. Defore and after treatment,best-corrected visual acuity,fundus photography,fundus fluoreseein angiograph（ FFA）, optical coherence tomography（ OCT） were examined. RESULTS： A total of 22 patients were treated with intravitreal injection of Conbercept had different degrees of increase in the mean visual acuity at 1wk,1,2 and3 mo. The difference is statistically significant（ P〈0. 05）.OCT images showthat the thickness of the central retinal thickness of the macular becomes thinner, and the difference is statistically significant（ P〈0. 05）. The FFA at3 mo showed a significant reduction in retinal leakage,obvious absorption of retinal hemorrhage.CONCLUSION： Intravitreal injection of anti-VEGF drugs Conbercept is an effective way to treat macular edema secondary to retinal vein occlusion,it is worth to promot,but the long- termefficacy and drug injection frequency still need to study further.